Amended Current Report Filing (8-k/a)
09 Dezembro 2022 - 6:50PM
Edgar (US Regulatory)
0000861838
false
0000861838
2022-09-28
2022-09-28
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
September 28, 2022
Idera Pharmaceuticals,
Inc.
(Exact name of registrant as specified in
its charter)
|
Delaware
(State of other jurisdiction of incorporation) |
001-31918
(Commission
File Number) |
04-1187261
(I.R.S. Employer
Identification No.) |
505
Eagleview Blvd., Suite 212
Exton, Pennsylvania
19341
(Address of principal executive offices)
Registrant’s telephone
number, including area code (484) 348-1600
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions :
| ¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
|
Trading
Symbol(s) |
|
Name of each exchange
on which registered |
| Common stock, $0.001 Par Value |
|
IDRA |
|
Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ¨
EXPLANATORY NOTE
On September 30,
2022, Idera Pharmaceuticals, Inc., a Delaware corporation (the “Company”), filed a Current Report
on Form 8-K announcing that on September 28, 2022 (the “Effective Date”), the Company
had acquired Aceragen, Inc., a Delaware corporation (“Aceragen”) pursuant to that certain Agreement and
Plan of Merger, dated as of the Effective Date (the “Merger Agreement”) by and among the Company, Bell Merger
Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of Idera (“First Merger Sub”), Bell Merger Sub II,
LLC, a Delaware limited liability company and wholly owned subsidiary of Idera (“Second Merger Sub”), and Aceragen. This Current
Report on Form 8-K/A amends and supplements the Current Report on Form 8-K filed on September 30,
2022 (the “September 2022 Form 8-K”) to provide the financial statements and pro forma
information required by Items 9.01(a) and 9.01(b) of Form 8-K. Additionally, this Current Report on Form 8-K/A provides an update with respect to the timing of a meeting by an independent Data Monitoring
Committee (the “iDMC”) to discuss the Company’s TERRA study.
The text of the September 2022 Form 8-K is incorporated
herein by reference. Capitalized terms not otherwise defined herein shall have the respective meanings ascribed to them in the September 2022 Form 8-K.
Item 8.01 Other Events.
As previously disclosed in
the Company’s Form 10-Q for the quarter ended September 30, 2022 and filed by the Company with the Securities and Exchange Commission
on November 14, 2022, the Company is conducting the TERRA study (NCT05105035), a phase 2 randomized, double-blind, placebo-controlled
study for the treatment of melioidosis in hospitalized patients with melioidosis. The Company previously disclosed that the iDMC, which
has responsibility for overseeing safety and efficacy data from the TERRA study, would meet during the fourth quarter of 2022. The iDMC
for the TERRA study is now expected to convene in the first quarter of 2023 to allow time for data entry and cleaning related to end of
year 2022 enrollment. The Company expects that iDMC will focus on the independent assessment of safety and aggregate clinical event
rates and then make recommendations for potential changes in eligibility criteria.
Item 9.01. Financial
Statements and Exhibits.
(a) Financial
Statements of Businesses Acquired.
The
audited consolidated financial statements and accompanying notes of Aceragen for the period March 2, 2021 (inception) through December 31,
2021 and the unaudited financial statements and accompanying notes of Aceragen for the six-month periods ended June 30,
2022 and 2021, are contained in the Company’s definitive proxy statement on Schedule 14A dated December 8, 2022 as Annexes
C and D thereto, respectively, and are incorporated herein by reference.
(b) Pro
Forma Financial Information.
The
unaudited pro forma combined financial information of the Company, including the unaudited pro forma combined balance sheet as of June 30,
2022, the unaudited pro forma combined statement of operations for the nine months ended September 30, 2022, the unaudited pro forma
combined statement of operations for the year ended December 31, 2021, and the notes related thereto are contained in the Company’s
definitive proxy statement on Schedule 14A dated December 8, 2022 as Annex E thereto are incorporated herein by reference.
Item 9.01. Financial
Statements and Exhibits.
(d) Exhibits
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: December 9, 2022 |
IDERA PHARMACEUTICALS, INC. |
| |
|
| |
By: |
/s/ Bryant D. Lim |
| |
|
Bryant D. Lim, Chief Business Officer and General Counsel |
Idera Pharmaceuticals (NASDAQ:IDRA)
Gráfico Histórico do Ativo
De Fev 2025 até Mar 2025
Idera Pharmaceuticals (NASDAQ:IDRA)
Gráfico Histórico do Ativo
De Mar 2024 até Mar 2025
